The expression of TET1 however did not vary significantly across the patient groups (Fig. 3f) or IPSS-R categories, giving rise to speculations about other mechanisms that can alter the 5-hmC levels in the BMNCs, a likely candidate being the 3rd paralog of TET proteins – TET3. Yet, analysis of publicly available AML-MR and MDS datasets (GSE5881 and GSE145733) from NCBI-GEO using GEO2R did not show any significant alteration of TET3 expression in AML-MR and MDS when compared to healthy controls (Fig. 3g). This evidence concerns the gene TET3 and acute myeloid leukemia.